Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Simons, P. J.
Right arrow Articles by Colven, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simons, P. J.
Right arrow Articles by Colven, R. M.

(Stroke. 2000;31:543.)
© 2000 American Heart Association, Inc.


Letters to the Editor

Cerebral Venous Thrombosis and the G20210A Mutation of Factor II

Pieter Jan Simons, MD Geert Vanhooren, MD

Stroke Unit, Department of Neurology, St Janshospitaal, Bruges, Belgium

To the Editor:

In addition to the article of Longstreth et al1 recently published in Stroke, we describe 2 cases of stroke due to cerebral venous thrombosis with the G20210A mutation as only risk factor.

After sequencing of the gene for human prothrombin (factor II) by Degen and Davie2 in 1987, a new mutation of prothrombin (G20210A) was described by Poort et al3 in 1996. It is a common mutation of this factor associated with an increased risk of venous (and possible arterial) thrombosis, as stated by Martinelli et al.4 The mutation can be detected by a polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) method, as described by Poort.3 Our laboratory uses this method.

Recently, we saw 2 patients with a definite diagnosis of cerebral venous thrombosis. No other known risk factor for cerebral venous thrombosis could be found. The finding of the abnormal mutation (G20210A) of factor II gene (both patients had a heterozygous state for the mutation) suggested this as etiology.

Patient 1 was a 42-year-old employee and moderate smoker. In his early thirties he had an arterial thrombectomy in a peripheral artery. In his family only his father had suffered a "stroke." He was admitted to our hospital with a first epileptic seizure, focal in origin. There was a venous infarction in the right frontal lobe. MR angiography (including venous phase) showed a typical stop in the frontal superior sagittal sinus, with loss of draining veins. None of the other tests associated with venous hypercoagulability showed . . . [Full Text of this Article]

W.T. Longstreth, Jr, MD, MPH

Department of Neurology

Roy M. Colven, MD

Department of Medicine, Division of Dermatology, University of Washington, Harborview Medical Center, Seattle, Washington